
Drug Development| Precision Oncology| Tissue-Agnostic Precision Medicine #Oncologist, #Phase1trials, #PrecisionMedicine. Tweets=My own.
New York, NY
Joined March 2015
- Tweets30.5K
- Following2.2K
- Followers41.6K
- Likes34.5K
⭐️Wearing purple tie 💜💜💜for #PancreaticCancerAwarenessDay.
A landmark year: the first RAS-targeted therapy approved for pancreatic cancer. Still far to go- but eager to work across all stakeholder groups to tackle this beast, with our novel agents including 100+ KRAS-targeted therapies in different stages of research + we need RAS inhibitors approved in a tissue-agnostic manner across all cancers.
Thanks, @scserendipity1 for making me wear a purple tie & arranging a big celebration in New York! 💜🗽@drallysonocean @PanCAN @letswinpc @OncoAlert @OncBrothers @oncodaily
Replying to @letswinpc
@letswinpc thank you 💜💜💜
Last night was brilliant. Thank you to all of the organisers and everyone involved. The speeches were so inspiring. There were tears, laughter, hope and a determination to keep on my improving care for our patients and their loved ones. One you shouldn’t have favourites..,
But @drallysonocean 🔥🔥🔥
Allyson you are such a ✨✨✨✨✨
Thank you all. New York’s Finest and much more 💜💜💜💜
Vivek Subbiah, MD retweeted
Delighted to host the #GICancerSummit26 at @nyulangone over the next two days, featuring talks on hepato-biliary and pancreatic cancers. @DrMhidalgo kicks off the summit highlighting @Perlmutter_CC and our multidisciplinary GI Cancer Center.
@MarkPochapin @JohnPLeonardMD
Vivek Subbiah, MD retweeted
Enjoying @Perlmutter_CC Pie Social with @Aiims1742 and @MichelleKimMD great day! @nyugrossman @nyugrossman
⭐️The future of oncology is bright & these amazing young people are why! Wonderful lunch with the oncology fellows @nyulangone @Perlmutter_CC @nyuniversity with an energizing Q&A on tumor-agnostics, drug development, clinical trials, building a career in oncology, why we need sequencing for all & @ASCO @ConquerCancerFd YIA & much much more…
⭐️Their curiosity+passion, recharged my inner batteries & made me even more excited to work alongside the next generation. We need every one of them here & everywhere, their ideas, talent, & determination, to tackle the emperor of all maladies! #Oncology #Mentorship @OncoAlert @oncodaily @Aiims1742 @JohnPLeonardMD
Vivek Subbiah, MD retweeted
💜💜💜💜💜
@VivekSubbiah and I will be in New York to support @letswinpc
@drallysonocean
Rumours that the two of us are getting a ‘purple rinse’ for our hair may have been exaggerated.,,
Thanks all in the pancreatic cancer community for your support, energy and enthusiasm to treat this disease
@allisonoconn @Aiims1742 @DanaFarber @GIMedOnc @KRASKickers
Thank you to 🌻🌻🌻🌻
This World Pancreatic Cancer Day, we invite you to join our movement.
💜 Wear purple and share a photo on social media. Don't forget to tag @PanCAN!
↪️ Spread awareness by sharing this post with your friends, family and community.
🔬 Learn what's next at our free virtual event: Pancreatic Cancer Early Detection: What’s on the Horizon?
✨ Make a gift to support leading-edge research and ensure everyone facing pancreatic cancer has somewhere to turn.
Every action taken today makes a difference. Together, we can make survival the expectation, not the exception, for patients facing this disease.
Visit 🔗 pancan.org/awareness for more.
Vivek Subbiah, MD retweeted
Every treatment available today started as a clinical trial. Let’s Win helps patients and families learn about emerging treatments and trials. letswinpc.org/treatments/fin… #WPCD

ALT Two people stand closely, gazing towards the horizon with thoughtful expressions. One is older, and the other appears younger. The sky is colorful, suggesting a sunrise or sunset. Text on the image promotes the importance of clinical trials and directs viewers to the Let's Win Pancreatic Cancer website for more information.
Vivek Subbiah, MD retweeted
2/ @VivekSubbiah on normalized membrane ratio of TROP2 as a predictor of outcomes with Dato-DXd in NSCLC:
nitter.gq/VivekSubbiah/status/21…
The TROP2/NMR/QCS/ paper is out @NatureMedicine 👉Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer
👉Scoring TROP2 IHC by eye doesn’t predict who benefits from TROP2 ADCs. Computational pathology does.
✅TROP2 QCS-NMR in TROPION-Lung01, NMR+ vs NMR–
👉Dato-DXd PFS 7.2 vs 4.0 mo (HR 0.40)
👉Docetaxel 4.1 vs 4.4 mo (HR 0.94)
👉An emerging predictive biomarker for Dato-DXd. #LCSM @OncoAlert @oncodaily nature.com/articles/s41591-0…
Vivek Subbiah, MD retweeted
We are recruiting for an outstanding clinical/translational leader and physician to serve as Section Chief, Thoracic Medical Oncology - contact me if interested @Perlmutter_CC @nyulangone @nyugrossman apply.interfolio.com/164896
Vivek Subbiah, MD retweeted
📣 Today #FDA approved giredestrant in combination with everolimus for adults with ER+/HER-/ESR1 mutated #MetastaticBreastCancer after prior endocrine therapy in adjuvant or advanced setting.
More detailed info here: fda.gov/drugs/cancer-approva….
#OncTwitter #bcsm #MedTwitter
Vivek Subbiah, MD retweeted
Clonal evolution. Wheler was here too but she left before the photo. Proud of these mentees and wonderful opportunity to see them at TargetCancer Foundation meeting for rare cancers. 🧨🦄🦓🎯💡👏
Vivek Subbiah, MD retweeted
Vivek Subbiah Reflects on Five Years of Progress and the Next Frontier in Rare Cancer Precision Oncology at Target Cancer Foundation’s Meeting
@VivekSubbiah @targetcancer
oncodaily.com/blog/vivek-sub…
Vivek Subbiah, MD retweeted
Vivek Subbiah Named Director of Early-Phase Drug Development and Rare Cancer Programs at NYU Langone
@VivekSubbiah
oncodaily.com/career/vivek-s…
RT @montypal: Critical guidance from the @AmericanCancer around #prostatecancer screening. These key changes will impact a much broader pop…
This quoted post is unavailable.
🚨Which clinical specialties are shielded from AI, and which are exposed? New @NEJM_AI , the authors measure how much of each specialty's work requires in-person physical interaction and what that means for AI's reach into practice.
👉"Physical Limits to AI Substitution across Physician Specialties- Implications for the Physician Workforce" @NEJM @NEJM_AI @OncoAlert ai.nejm.org/doi/full/10.1056…
🚨⭐️Your Outlook email may not be working & your flight may be delayed ✈️ so you might have a few minutes to read our Perspective, just published hot off the press @Nature @Nature_NPJ
👉Open access, free for all to read - at least @X & internet are working :) #precisionmedicine #AI
👉"AI-based prediction of actionable genomic alterations from H&E-stained slides" 🔬
👉Tissue exhaustion & slow turnaround still keep patients from the right targeted therapy. Deep learning models can now predict actionable genomic alterations directly from routine H&E, and the prospective EAGLE (EGFR, NSCLC) and ANNAR (FGFR, urothelial) studies show this holds across diverse global cohorts.
👉Near-instant, non-destructive results let us triage patients for molecular testing or clinical trials at the time of diagnosis. Every lab in the world makes an H&E slide, and this puts molecular information within reach of all of them @OncoAlert @oncodaily
nature.com/articles/s41698-0…
Vivek Subbiah, MD retweeted
Definitely best meeting for rare cancers. Honored to chair meeting and to hear Subbiah amazing talk 🔥🔥🦄🦓
⭐️One of my favorite meetings of the year is today: Target Cancer Foundation's Rare Cancer Precision Oncology meeting. @targetcancer @Dr_R_Kurzrock
⭐️Looking forward to delivering my lecture “AGNOSTIC BY DESIGN: Five Years That Redrew the Map of Rare Cancer Precision Oncology, & the Next Frontier” 🧬🎯🚀@OncoAlert @oncodaily @OncBrothers @OpenMedInsights @OpenMedKate
#TCFTargetcancer2026
#RareCancer #PrecisionOncology
targetcancer.org/research/th…
⭐️One of my favorite meetings of the year is today: Target Cancer Foundation's Rare Cancer Precision Oncology meeting. @targetcancer @Dr_R_Kurzrock
⭐️Looking forward to delivering my lecture “AGNOSTIC BY DESIGN: Five Years That Redrew the Map of Rare Cancer Precision Oncology, & the Next Frontier” 🧬🎯🚀@OncoAlert @oncodaily @OncBrothers @OpenMedInsights @OpenMedKate
#TCFTargetcancer2026
#RareCancer #PrecisionOncology
targetcancer.org/research/th…
The TROP2/NMR/QCS/ paper is out @NatureMedicine 👉Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer
👉Scoring TROP2 IHC by eye doesn’t predict who benefits from TROP2 ADCs. Computational pathology does.
✅TROP2 QCS-NMR in TROPION-Lung01, NMR+ vs NMR–
👉Dato-DXd PFS 7.2 vs 4.0 mo (HR 0.40)
👉Docetaxel 4.1 vs 4.4 mo (HR 0.94)
👉An emerging predictive biomarker for Dato-DXd. #LCSM @OncoAlert @oncodaily nature.com/articles/s41591-0…
Vivek Subbiah, MD retweeted
Great things happen in pairs!!
National Leader in Cancer Symptom Management, Ishwaria Subbiah, MD, Joins @Perlmutter_CC @nyulangone
Welcome to PCC and New York City @IshwariaMD - we are so excited to have you and your family here.
@JohnPLeonardMD
nyulangone.org/news/national…












































